O
INFI

OrbiMed’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

OrbiMed’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-150,000
Closed -$2.62M – 136
2013
Q3 		$2.62M Buy
+150,000
New +$2.87M 0.05% 117

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed's INFI Position: Q4 2017 in Review

OrbiMed sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q4 2017, closing a stake of 2,207,245 shares — an estimated $2.94M sold.

OrbiMed first reported a position in INFI in Q2 2013 and held it in 18 quarters. The position peaked at $80M in Q3 2013. 65 funds tracked by Wall St. Rank hold INFI as of Q4 2017.

  • OrbiMed reported no remaining Infinity Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • OrbiMed sold 2,207,245 Infinity Pharmaceuticals, Inc. shares in Q4 2017, an estimated $2.94M.
  • OrbiMed first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 18 quarters.
  • OrbiMed's Infinity Pharmaceuticals, Inc. position peaked at $80M in Q3 2013.
  • 65 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q4 2017.

Based on OrbiMed's 13F filing for Q4 2017, filed 14 Feb 2018.